PR Newswire Clinical TrialsOriginal article
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026
ConferenceASC36_35FDCPositive
AI Analysis
Summary
Ascletis Pharma presented preclinical data for ASC36_35FDC at EASD 2026, showing potential for once-monthly to once-quarterly dosing with robust weight-loss effects. The data demonstrates the drug candidate's potential as a long-acting obesity therapeutic.
Outcome Details
Preclinical data presented demonstrating potential for once-monthly to once-quarterly dosing and robust weight-loss
Importance:5/10
Sentiment:
0.60
obesityweight-losspreclinicalEASD 2026long-acting formulation
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 2, 2026 9:00 AM